Business Wire

Angelini Announces the Launch on the Italian Market of an Innovative Active Wound Cleanser Developed by the Swiss Company APR

Del

The leading Italian pharmaceutical company Angelini has started the promotion and marketing of a new active wound cleanser in Italian hospitals and wound therapy centers. The innovative acid-oxidizing solution contains hypoclorous acid and is indicated for the treatment of chronic wounds. The product has been acquired based on an exclusive partnership between Angelini and the Swiss Company APR Applied Pharma Research, the owner and developer of the proprietary, patented technology TEHCLO®, which enables the production of this acidic and super-oxidizing solution. This solution creates an unfavorable environment for the growth of microorganisms and may favor the release of oxygen in the injured tissues. The new acid-oxidizing wound cleanser solution is indicated for use in the debridement, irrigation, cleansing and moistening of acute and chronic wounds like diabetic foot ulcers, pressure ulcers, lower legs ulcers and vascular ulcers.

In the field of Wound Care, Angelini is now able to provide healthcare professionals with a range of wound treatment options from active cleansing, to antisepsis and epithelialization support.

“With the launch of this product, Angelini aims at strengthening its position in the Wound Care therapeutic area fulfilling a medical need of the scientific community, which encompasses the shift from a passive method of mere cleansing to an active process supporting the physiological healing process.” states Fabio De Luca, Chief Commercial Officer Italy of Angelini Pharma Division.

“We are very proud to see this product on the Italian market“ said Paolo Galfetti, Chief Executive Officer of APR “as it represents a new and unique option to actively cleanse any kind of wound. While cleansing the wound bed, this innovative product is able to modulate the lesion’s microenvironment contributing to the control of the microbial burden, protecting from the risk of local infection, as well as sustaining physiological healing. We believe that this product, for its adaptable use along the continuum of wound care, offers the opportunity to exploit the growth forecasted in the wound cleansing market on an European basis, which is expected to hit a total value of $220 Mio in 2019. ”

The new acid-oxidizing solution has been developed based on APR’s proprietary patented technology TEHCLO®, enabling the production of an acidic and super-oxidizing solution characterized by pH<3, RedOx >1000mV and stabilized hypochlorous acid (>95% of free chlorine species).

It is intended for use in the debridement, irrigation, cleansing and moistening of acute and chronic wounds (e.g. diabetic foot ulcers, pressure ulcers, lower leg ulcers, vascular ulcers), post-surgical wounds, cuts, abrasions, burns and other lesions. As it contains hypochlorous acid as a preservative, it can prevent wound contamination by exerting a local antimicrobial effect on the wound surface. The convenient and easy-to-use spray formulation completes the product’s profile, providing healthcare professionals with a new tool for an optimized wound care.

The product is certified in EU as Class III Medical Device according to the rigorous European regulation.

About APR – APPLIED PHARMA RESEARCH

APR is a Swiss, independent developer of science driven, patent protected healthcare products. The Company identifies, develops and licenses science driven, value added products designed to address patient or consumer needs in niche or rare therapeutic areas on a global basis. In particular, APR’s business model is currently focused on 2 (two) pillars: (i) internally developed and financed (alone or together with our co-development partners) proprietary, value added products to be licensed to healthcare companies for their commercialization, and (ii) support to third party projects by offering added value R&D services under contract and fee for service arrangements. APR has a balanced pipeline of revenue generating branded products marketed in all major markets combined with a compelling pipeline of products at different stage of development. APR has entered into licensing and partnership agreements with pharmaceutical companies in over 70 countries with international sales on a worldwide basis.

For press releases and other company information, please visit: www.apr.ch

About ANGELINI

Angelini is a privately-held, mid-sized international manufacturer and marketer of pharmaceutical and healthcare products in the pharmaceutical and mass-market sectors. Founded in Italy in 1919, the group has branches in 20 countries and employs 5.000 people. The pharmaceutical sector is the core business of the group, representing over 50% of the company’s over €1.4 billion 2014 revenue.

Angelini pharmaceutical products are available in over 60 countries through its branches and an extensive network of licensees and strategic agreements with local pharmaceutical companies. Over the years, the R&D department identified molecules of world importance like benzydamine and trazodone and is currently engaged in research projects in the field of pain and inflammation, CNS and infection.

At an international level, the company focuses mainly on pain relief, inflammation, CNS, cold & flu, oral care & sore throat, gynecology, disinfection. In Italy, Angelini is among the leading pharmaceutical companies in terms of volumes, one of the firms with the highest growth rate in the prescription drugs market, and a leader in self-medication sector.

www.angelinipharma.com

Contact information

APR:
PAOLO GALFETTI (CEO)
Tel: +41 91 695 70 20
paolo.galfetti@apr.ch | www.apr.ch
or
ANGELINI:
FABIO PIERONI (Corporate Communication Director)
Tel: +39 06 78053366
f.pieroni@angelini.it | www.angelinipharma.com

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

SmartStream and Credit Suisse Expand their Agreement from the Processing of Invoices and Reconciliations to Now Include Listed Derivatives Brokerage Fees18.10.2017 12:00Pressemelding

SmartStream Technologies, the financial Transaction Lifecycle Management (TLM®) solutions provider, today announced that its original agreement with Credit Suisse was recently expanded to include the processing of Listed Derivatives Brokerage fees which began in February of this year. This expansion in SmartStream’s partnership with Credit Suisse complements its existing managed service solution for the processing of invoices and reconciliations within Credit Suisse’s OTC Fixed Income Derivatives, US Listed Equity Options and Cash Equities businesses across brokerage, clearing and exchange fees operations, which began in June of 2016. The managed service enables the bank to advance the operational efficiencies created through the use of the utility-based solutions offered by SmartStream, utilizing their proprietary execution fees and expense management software. By centralizing the ent

Biogen Confirms Commitment to Tackle Multiple Sclerosis Through Comprehensive Approach18.10.2017 11:30Pressemelding

Biogen (NASDAQ: BIIB) confirms its comprehensive approach to tackle multiple sclerosis (MS) at the seventh Joint Meeting of the European Committee for Treatment and Research in MS and Americas Committee for Treatment and Research in MS (ECTRIMS-ACTRIMS; 25 – 28 October). “With more than 25 years of scientific leadership in MS, Biogen’s commitment is unwavering,” said Michael Ehlers, executive vice president, Research & Development at Biogen. “Our expertise puts Biogen in a unique position with a comprehensive approach including active research and clinical development on how to repair the damage to the central nervous system from relapsing forms of MS, a portfolio of new drug candidates that we are advancing to the clinic, our collaboration to identify a digital biomarker, our focus to advance understanding of the disease through global data collection with MS PATHS, active pursuit

Scientist.com Collaborates With UKCRC Tissue Directory and Coordination Centre to Ensure Quality of Human Biosample Acquisition Globally18.10.2017 11:01Pressemelding

Scientist.com, the world’s leading marketplace for outsourced scientific services, today announced that it is entering into a collaboration with the UKCRC Tissue Directory and Coordination Centre (UKCRC TDCC) to support the work of biobanks throughout the United Kingdom. The partnership will enable drug R&D to move forward more quickly by making large collections of prescreened human biological samples available for scientific research. Through the new COMPLI™ feature, Scientist.com provides a simple, efficient and effective way of increasing the visibility and accessibility of biobanks’ human biological samples collections, which support new medical research. COMPLI™ introduces a common, comprehensive process and supply agreement supporting access to human biosamples. The goal is to enable biobanks to more easily connect with researchers in the pharmaceutical and biotech indust

Assurant to Acquire the Warranty Group in Transaction Valued at $2.5 Billion18.10.2017 10:30Pressemelding

Assurant, Inc. (NYSE:AIZ), a premier global provider of risk management solutions, and The Warranty Group, a leading global provider of protection plans and related programs, and a portfolio company of TPG Capital, today announced that they have entered into a definitive agreement to combine operations, with Assurant shareholders retaining majority ownership of the combined company. The transaction is valued at approximately $2.5 billion and is expected to close in the first half of 2018, subject to shareholder and regulatory approvals, and other customary closing conditions. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171018005269/en/ The transaction will significantly advance Assurant’s strategy in the global lifestyle market with an attractive product and client portfolio, diversified growth profile and a deeper glob

Boost the Connectivity and Memory on Your Phone with FuZion18.10.2017 09:47Pressemelding

IDEMIA (formerly known as OT-Morpho), the global leader in trusted identities for an increasingly digital world, today announces the solution for a problem everyone encounters: the choice between connectivity and memory for one’s smartphone. With FuZion, a fantastic device combining the technologies of a SIM card with a microSD card, users will never have to make this choice again. Nowadays, most people need to have two SIM cards, one for personal use and the other for a professional one. At the same time, people require their smartphone to have a lot of memory. That is why today, more and more smartphones have a dual SIM tray, with a hybrid slot for two SIM cards or for one SIM card and a microSD card. With FuZion, no compromises: users can simultaneously have two SIM cards and a microSD card in their phone. FuZion is available for more than 50 smartphone models from

Capgemini Gives Technology a Human Touch, with a New Brand Identity Designed by BrandPie.18.10.2017 08:30Pressemelding

Capgemini, one of the world’s leading global technology and consulting firms, yesterday launched its new brand identity, designed by strategic brand consultancy BrandPie. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171018005101/en/ Capgemini's new brand identity, designed by BrandPie BrandPie worked in close collaboration with Capgemini’s leadership team over 15 months to create a dynamic digital-first brand identity and wordmark, inspired by the handwriting of Serge Kampf, Capgemini’s founder. Meanwhile, its iconic spade emblem has been redrawn to reflect the world the business is now in. Coinciding with the Group’s 50th anniversary, this is the first overhaul of Capgemini’s brand identity since 2004, and has been crafted to ensure that it remains ahead of its peers in its

I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.

Besøk vårt presserom